ARTHEx Biotech

ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative drugs by modulating microRNAs. The company’s lead investigational compound, ATX-01, is advancing in clinical development for the treatment of Type 1 Myotonic Dystrophy (DM1), a rare progressive muscle-wasting disease. ARTHEx is also advancing its internal discovery engine to identify and develop microRNA modulators for other diseases with high unmet medical needs, including genetically driven conditions such as DM1. The company is headquartered in Valencia, Spain.